The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

77%), regardless of whether the pathogens were susceptible or resistant to amoxicillin-clavulanate. Persistent UTIs occurred in 8 amoxicillin-clavulanate recipients and 1 ciprofloxacin recipient ...

for uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older. The small-molecule drug is the first in a new class of oral antibiotics for ...

Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children over the age of 12 with uncomplicated UTIs caused by bacteria including E.

Lifestyle adjustments can help prevent UTIs. While not a proven cure, cranberry products and D-mannose supplements may help ...

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or uUTIs, successfully and safely.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In kids with ...

Panelists discuss how fluoroquinolones are generally reserved for uncomplicated urinary tract infections (UTIs) only when first-line options are contraindicated or pathogen resistance is confirmed, ...

According to a new research, in children with febrile urinary tract infections, an individualized antibiotic regimen—stopping ...